Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T

NCT06134232 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

400

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Interventions

DRUG: Sipuleucel-T Injection

Sponsor

Dendreon

Collaborators

[object Object]
[object Object]